




Instance: composition-en-beff2655528d75e602c405816fbf6082
InstanceOf: CompositionUvEpi
Title: "Composition for novoseven Package Leaflet"
Description:  "Composition for novoseven Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp19f202467812b15f4eac52e395f85d01)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - novoseven"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Overleaf: Instructions on how to use NovoSeven </p>         </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What NovoSeven is and what it is used for </li>
<li>What you need to know before you use NovoSeven </li>
<li>How to use NovoSeven </li>
<li>Possible side effects </li>
<li>How to store NovoSeven </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What novoseven is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What novoseven is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>NovoSeven is a blood coagulation factor. It works by making the blood clot at the site of bleeding, 
when the body's own clotting factors are not working. </p>
<p>NovoSeven is used to treat bleeding, and to prevent excessive bleeding after surgery or other 
important treatments. Early treatment with NovoSeven reduces how much you bleed and for how long. 
It works in all types of bleeds, including joint bleeds. This reduces the need for hospitalisation and 
days absent from work and school. 
It is used in certain groups of people: 
* If you were born with haemophilia and do not respond normally to factors VIII or IX treatment 
* If you have acquired haemophilia 
* If you have Factor VII deficiency 
* If you have Glanzmann s thrombasthenia (a bleeding disorder) and your condition cannot be 
treated effectively with platelet transfusion, or if platelets are not readily available. </p>
<p>NovoSeven can also be given to you by a doctor to treat heavy bleeding after delivery of your baby, 
even if you do not have a bleeding disorder. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take novoseven"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take novoseven"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use NovoSeven 
* If you are allergic to eptacog alfa (active compound of NovoSeven) or any of the other 
ingredients in this medicine (listed in section 6). 
* If you are allergic to mouse, hamster or cow proteins (such as cows  milk). </p>
<p>If any of these apply to you, do not use NovoSeven. Talk to your doctor. </p>
<p>Warnings and precautions 
Before treatment with NovoSeven, make sure your doctor knows: 
* If you have just had surgery 
* If you recently had a crush injury 
* If your arteries are narrowed by disease (atherosclerosis) 
* If you have an increased risk of blood clots (thrombosis) 
* If you have severe liver disease 
* If you have a serious blood infection 
* If you are prone to disseminated intravascular coagulation (DIC, a condition where blood clots 
develop throughout the blood stream) you must be carefully monitored. </p>
<p>If any of these conditions apply to you, talk to your doctor before using the injection. </p>
<p>Other medicines and NovoSeven 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Do not use NovoSeven at the same time as prothrombin complex concentrates or rFXIII. You should 
talk to your doctor before using NovoSeven if you also use Factor VIII or IX products. </p>
<p>There is limited experience of using NovoSeven together with medicines called antifibrinolytic drugs 
(such as aminocaproic acid or tranexamic acid) which are also used to control bleeding. You should 
talk to your doctor before using NovoSeven with these medicines. </p>
<p>Pregnancy, breast-feeding and fertility 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before you use NovoSeven. </p>
<p>Driving and using machines<br />
There are no studies on the effect of NovoSeven on the ability to drive and use machines. However, 
there is no medical reason to think that it would affect your ability. </p>
<p>NovoSeven contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per injection, i.e. essentially  sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take novoseven"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take novoseven"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The NovoSeven powder must be reconstituted with its solvent and injected into a vein. See overleaf 
for detailed instructions. </p>
<p>When to treat yourself 
Start treatment of a bleed as early as possible, ideally within 2 hours. 
* In cases of a mild or moderate bleed, you should treat yourself as early as possible, ideally at 
home. 
* In case of a severe bleed you should contact your doctor. Usually severe bleeds are treated at the 
hospital and you can give yourself the first NovoSeven dose on the way there. </p>
<p>Do not treat yourself for longer than 24 hours without consulting your doctor. 
* Each time you use NovoSeven, tell your doctor or hospital as soon as possible. 
* If bleeding is not controlled within 24 hours, contact your doctor immediately. You will usually 
need hospital care. </p>
<p>Dose 
The first dose should be given as early as possible after bleeding has started. Talk to your doctor about 
when to use the injections and how long to keep using them. 
The dose will be worked out by your doctor, based on your body weight, condition and type of bleed. 
To achieve the best results, follow the prescribed dose carefully. Your doctor might change the dose. </p>
<p>If you have haemophilia: 
The usual dose is 90 micrograms for every 1 kilogram you weigh; you can repeat the injection every 
2 3 hours until bleeding is controlled. 
Your doctor may recommend a single dose of 270 micrograms for every 1 kilogram you weigh. There 
is no clinical experience in people over 65 using this single dose. </p>
<p>If you have Factor VII deficiency: 
The usual dose range is 15 to 30 micrograms for every 1 kilogram you weigh, for each injection. </p>
<p>If you have Glanzmann s thrombasthenia: 
The usual dose is 90 micrograms (range is 80 to 120 micrograms) for every 1 kilogram you weigh, for 
each injection. </p>
<p>If you inject more NovoSeven than you should 
If you inject too much NovoSeven, get medical advice at once. </p>
<p>If you forget an injection of NovoSeven 
If you forget an injection, or if you want to stop the treatment, get your doctor's advice. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Serious side effects<br />
Rare (may affect up to 1 in 1,000 treatment episodes) 
* Allergic, hypersensitivity or anaphylactic reactions. Signs may include skin rashes, itching, 
flushing and hives; wheezing or difficulty breathing; feeling faint or dizzy; and severe swelling 
of the lips or throat, or at the injection site. 
* Blood clots in arteries in the heart (which could lead to a heart attack or angina), in the brain 
(which could lead to a stroke) or in the intestine and kidneys. Signs may include severe pain in 
the chest, breathlessness, confusion, difficulty with speech or movement (paralysis) or 
abdominal pain. </p>
<p>Uncommon (may affect up to 1 in 100 treatment episodes) 
* Blood clots in the veins in lungs, legs, liver, kidneys or at site of injection. Signs may include 
difficulty in breathing, red and painful swelling in the leg and abdominal pain. 
* Lack of effect or decreased response to treatment. </p>
<p>If you notice any of these serious side effects, get medical help immediately. Explain that you 
have been using NovoSeven. </p>
<p>Remind your doctor if you have a history of allergic reactions as you may need to be monitored more 
carefully. In most cases of blood clots, the patients were predisposed to blood clotting disorders. </p>
<p>Other rare side effects 
(may affect up to 1 in 1,000 treatment episodes)<br />
* Nausea (feeling sick) 
* Headache 
* Changes in some liver and blood tests. </p>
<p>Other uncommon side effects 
(may affect up to 1 in 100 treatment episodes) 
* Allergic skin reactions including rash, itching and hives 
* Fever. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this 
leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. 
By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store novoseven"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store novoseven"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <ul>
<li>Keep this medicine out of the sight and reach of children. </li>
<li>Do not use this medicine after the expiry date that is stated on the carton. The expiry date refers 
to the last day of that month. </li>
<li>Store powder and solvent below 25 C. </li>
<li>Store powder and solvent protected from light. </li>
<li>Do not freeze. </li>
<li>Use NovoSeven at once after mixing the powder with the solvent to avoid infection. If you 
cannot use it immediately, after it has been mixed, you should store it in the vial with the vial 
adapter and syringe still attached in a refrigerator at 2 C to 8 C for no longer than 24 hours. Do 
not freeze the mixed NovoSeven solution and keep it protected from light. Do not store the 
solution without advice from your doctor or nurse. </li>
<li>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist 
how to throw away medicines you no longer use. These measures will help protect the 
environment. </li>
</ul>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What NovoSeven contains 
* The active substance is recombinant coagulation factor VIIa (activated eptacog alfa). 
* The other ingredients in the powder are sodium chloride, calcium chloride dihydrate, 
glycylglycine, polysorbate 80, mannitol, sucrose, methionine, hydrochloric acid, sodium 
hydroxide. The ingredients in the solvent are histidine, hydrochloric acid, sodium hydroxide, 
water for injections. </p>
<p>The powder for solution for injection contains: 1 mg/vial (corresponding to 50 KIU/vial), 2 mg/vial 
(corresponding to 100 KIU/vial), 5 mg/vial (corresponding to 250 KIU/vial) or 8 mg/vial 
(corresponding to 400 KIU/vial). 
After reconstitution, 1 ml of the solution contains 1 mg eptacog alfa (activated). 
1 KIU equals 1,000 IU (International Units). </p>
<p>What NovoSeven looks like and contents of the pack 
The powder vial contains white powder and the pre-filled syringe contains a clear colourless solution. 
The reconstituted solution is colourless. Do not use the reconstituted solution if you notice particles in 
it or if it is discoloured. </p>
<p>Each NovoSeven pack contains: 
* 1 vial with white powder for solution for injection 
* 1 vial adapter 
* 1 pre-filled syringe with solvent for reconstitution 
* 1 plunger rod </p>
<p>Pack sizes: 1 mg (50 KIU), 2 mg (100 KIU), 5 mg (250 KIU) and 8 mg (400 KIU). </p>
<p>Please refer to outer packaging for present pack size. </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Novo Nordisk A/S 
Novo All<br />
DK-2880 Bagsv rd, Denmark </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu. </p>
<p>Instructions on how to use NovoSeven </p>
<p>READ THESE INSTRUCTIONS CAREFULLY BEFORE USING NOVOSEVEN </p>
<p>NovoSeven is supplied as a powder. Before injection (administration) it must be reconstituted with the solvent 
supplied in the syringe. The solvent is a histidine solution. The reconstituted NovoSeven must be injected into 
your vein (intravenous injection). The equipment in this package is designed to reconstitute and inject 
NovoSeven. </p>
<p>You will also need an administration set (tubing and butterfly needle, sterile alcohol swabs, gauze pads and 
plasters). These devices are not included in the NovoSeven package. </p>
<p>Do not use the equipment without proper training from your doctor or nurse. </p>
<p>Always wash your hands and ensure that the area around you is clean. </p>
<p>When you prepare and inject medication directly into the vein, it is important to use a clean and germ free 
(aseptic) technique. Improper technique can introduce germs that can infect the blood. </p>
<p>Do not open the equipment until you are ready to use it. </p>
<p>Do not use the equipment if it has been dropped, or if it is damaged. Use a new package instead. </p>
<p>Do not use the equipment if it is expired. Use a new package instead. The expiry date is printed after  EXP<br />
on the outer carton, on the vial, on the vial adapter and on the pre-filled syringe.  </p>
<p>Do not use the equipment if you suspect it is contaminated. Use a new package instead. </p>
<p>Do not dispose of any of the items until after you have injected the reconstituted solution. </p>
<p>The equipment is for single use only. </p>
<p>Contents </p>
<p>The package contains: </p>
<ul>
<li>1 vial with NovoSeven powder </li>
<li>1 vial adapter </li>
<li>1 pre-filled syringe with solvent </li>
<li>1 plunger rod (placed under the syringe) </li>
</ul>
<p>Overview 
Plastic cap 
Rubber stopper 
(under plastic cap) 
Vial with NovoSeven powder </p>
<p>Vial adapter 
Protective cap 
Spike 
(under protective paper) 
Protective 
paper </p>
<p>Pre-filled syringe with solvent 
Syringe tip 
(under syringe 
cap) 
Scale 
Plunger 
Syringe cap </p>
<p>Plunger rod 
Thread 
Wide top 
end </p>
<ol>
<li>
<p>Prepare the vial and the syringe </p>
</li>
<li>
<p>Take out the number of NovoSeven packages 
you need. </p>
</li>
<li>
<p>Check the expiry date. </p>
</li>
<li>
<p>Check the name, strength and colour of the 
package, to make sure it contains the correct 
product. </p>
</li>
<li>
<p>Wash your hands and dry them properly using a 
clean towel or air dry. </p>
</li>
<li>
<p>Take the vial, the vial adapter and the pre-filled 
syringe out of the carton. Leave the plunger rod 
untouched in the carton. </p>
</li>
<li>
<p>Bring the vial and the pre-filled syringe to 
room temperature (not above 37 C). You can 
do this by holding them in your hands until they 
feel as warm as your hands. </p>
</li>
<li>
<p>Do not use any other way to warm the vial and 
pre-filled syringe. </p>
</li>
</ol>
<p>A </p>
<ul>
<li>
<p>Remove the plastic cap from the vial. 
If the plastic cap is loose or missing, do not 
use the vial. </p>
</li>
<li>
<p>Wipe the rubber stopper with a sterile alcohol 
swab and allow it to air dry for a few seconds 
before use to ensure that it is as germ free as 
possible. </p>
</li>
<li>
<p>Do not touch the rubber stopper with your 
fingers as this can transfer germs. </p>
</li>
</ul>
<p>B </p>
<ol>
<li>
<p>Attach the vial adapter </p>
</li>
<li>
<p>Remove the protective paper from the vial 
adapter. </p>
</li>
</ol>
<p>If the protective paper is not fully sealed or if 
it is broken, do not use the vial adapter. </p>
<p>Do not take the vial adapter out of the 
protective cap with your fingers. If you touch 
the spike on the vial adapter germs from your 
fingers can be transferred. </p>
<p>C </p>
<ul>
<li>
<p>Place the vial on a flat and solid surface. </p>
</li>
<li>
<p>Turn over the protective cap, and snap the vial 
adapter onto the vial.  </p>
</li>
</ul>
<p>Once attached, do not remove the vial adapter 
from the vial. </p>
<p>D </p>
<ul>
<li>Lightly squeeze the protective cap with your 
thumb and index finger as shown. </li>
</ul>
<p>Remove the protective cap from the vial 
adapter. </p>
<p>Do not lift the vial adapter from the vial when 
removing the protective cap. </p>
<p>E </p>
<ol>
<li>
<p>Attach the plunger rod and the syringe </p>
</li>
<li>
<p>Grasp the plunger rod by the wide top-end and 
take it out of the carton. Do not touch the sides 
or the thread of the plunger rod. If you touch 
the sides or the thread, germs from your fingers 
can be transferred. </p>
</li>
</ol>
<p>Immediately connect the plunger rod to the 
syringe by turning it clockwise into the plunger 
inside the pre-filled syringe until resistance is 
felt. </p>
<p>F </p>
<ul>
<li>Remove the syringe cap from the pre-filled 
syringe by bending it down until the perforation 
breaks. </li>
</ul>
<p>Do not touch the syringe tip under the syringe 
cap. If you touch the syringe tip, germs from 
your fingers can be transferred. </p>
<p>If the syringe cap is loose or missing, do not 
use the pre-filled syringe. </p>
<p>G </p>
<ul>
<li>Screw the pre-filled syringe securely onto the 
vial adapter until resistance is felt. </li>
</ul>
<p>H </p>
<ol>
<li>
<p>Reconstitute the powder with the solvent </p>
</li>
<li>
<p>Hold the pre-filled syringe slightly tilted with 
the vial pointing downwards. </p>
</li>
<li>
<p>Push the plunger rod to inject all the solvent 
into the vial. </p>
</li>
</ol>
<p>I </p>
<ul>
<li>Keep the plunger rod pressed down and swirl 
the vial gently until all the powder is dissolved. </li>
</ul>
<p>Do not shake the vial as this will cause 
foaming. </p>
<ul>
<li>Check the reconstituted solution. It must be 
colourless. If you notice visible particles or 
discolouration, do not use it. Use a new 
package instead. </li>
</ul>
<p>J </p>
<p>Use the reconstituted NovoSeven at once to avoid infections. </p>
<p>If you cannot use it at once, see section 5 How to store NovoSeven on the other side of this leaflet. Do not 
store the reconstituted solution without advice from your doctor or nurse. </p>
<p>(I) 
If your dose requires more than one vial, repeat steps A to J with additional vials, vial adapters and pre-filled 
syringes until you have reached your required dose. 
* Keep the plunger rod pushed completely in.  </p>
<ul>
<li>
<p>Turn the syringe with the vial upside down.  </p>
</li>
<li>
<p>Stop pushing the plunger rod and let it move 
back on its own while the reconstituted solution 
fills the syringe. </p>
</li>
<li>
<p>Pull the plunger rod slightly downwards to 
draw the reconstituted solution into the syringe. </p>
</li>
<li>
<p>In case you only need part of the reconstituted 
solution, use the scale on the syringe to see how 
much of the solution you withdraw, as instructed 
by your doctor or nurse. </p>
</li>
<li>
<p>If, at any point, there is too much air in the 
syringe, inject the air back into the vial. </p>
</li>
<li>
<p>While holding the vial upside down, tap the 
syringe gently to let any air bubbles rise to the 
top. </p>
</li>
<li>
<p>Push the plunger rod slowly until all air 
bubbles are gone. </p>
</li>
</ul>
<p>K </p>
<ul>
<li>
<p>Unscrew the vial adapter with the vial.  </p>
</li>
<li>
<p>Do not touch the syringe tip. If you touch the 
syringe tip, germs from your fingers can be 
transferred. </p>
</li>
</ul>
<p>L </p>
<p>Injecting NovoSeven with pre-filled syringe via needleless connectors for intravenous (IV) catheters </p>
<p>Caution: The pre-filled syringe is made of glass and is designed to be compatible with standard luer-lock 
connections. Some needleless connectors with an internal spike are incompatible with the pre-filled syringe. 
This incompatibility may prevent administration of the drug and/or result in damage to the needleless 
connector. </p>
<p>Follow the instructions for use for the needleless connector. Administration through a needleless connector may 
require withdrawal of the reconstituted solution into a standard 10 ml sterile luer-lock plastic syringe. This 
should be done right after step J. </p>
<ol>
<li>Inject the reconstituted solution </li>
</ol>
<p>NovoSeven is now ready to inject into your vein.  </p>
<ul>
<li>
<p>Inject the reconstituted solution as instructed by your doctor or nurse. </p>
</li>
<li>
<p>Inject slowly over 2 to 5 minutes. </p>
</li>
</ul>
<p>Injecting the solution via a central venous access device (CVAD) such as a central venous catheter or a 
subcutaneous port: 
* Use a clean and germ free (aseptic) technique. Follow the instructions for proper use for your connector 
and CVAD in consultation with your doctor or nurse. 
* Injecting into a CVAD may require using a sterile 10 ml plastic syringe for withdrawal of the 
reconstituted solution. 
* If the CVAD line needs to be flushed before or after NovoSeven injection, use sodium chloride 9 mg/ml 
solution for injection. </p>
<p>Disposal </p>
<ul>
<li>
<p>After injection, safely dispose of the syringe 
with the administration set, the vial with the vial 
adapter, any unused NovoSeven and other waste 
materials as instructed by your doctor or nurse.  </p>
</li>
<li>
<p>Do not throw it out with the ordinary household 
waste. </p>
</li>
</ul>
<p>M </p>
<p>Do not disassemble the equipment before disposal.  </p>
<p>Do not reuse the equipment. </p>         </div>"""      



Instance: composition-da-beff2655528d75e602c405816fbf6082
InstanceOf: CompositionUvEpi
Title: "Composition for novoseven Package Leaflet"
Description:  "Composition for novoseven Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp19f202467812b15f4eac52e395f85d01)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - novoseven"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Den anden side af indlægssedlen: NovoSeven Brugervejledning </p>         </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at bruge NovoSeven 
3. Sådan skal du bruge NovoSeven 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What novoseven is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What novoseven is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>NovoSeven er en blodkoagulationsfaktor. Det virker hos patienter, hvis egne koagulationsfaktorer ikke 
virker, ved at få blodet til at koagulere på det sted, hvor blødningen er opstået. </p>
<p>NovoSeven anvendes til behandling af blødninger og til forebyggelse af kraftig blødning efter kirurgi 
eller andre vigtige behandlinger. Tidlig behandling med NovoSeven reducerer mængden og 
varigheden af blødningen. Det virker for alle typer blødninger, inklusiv blødninger i led. Det reducerer 
behovet for indlæggelse og fraværsdage fra skole og arbejde. 
Det anvendes hos bestemte grupper af mennesker: </p>
<ul>
<li>
<p>Hvis du blev født med hæmofili og ikke reagerer normalt på faktor VIII eller IX behandling </p>
</li>
<li>
<p>Hvis du har erhvervet hæmofili </p>
</li>
<li>
<p>Hvis du har faktor VII-mangel </p>
</li>
<li>
<p>Hvis du har Glanzmanns trombasteni (en blødersygdom), og din tilstand ikke kan behandles 
med blodpladetransfusion, eller hvis blodpladerne ikke er tilgængelige. </p>
</li>
</ul>
<p>NovoSeven kan også gives til dig af en læge til behandling af kraftig blødning efter fødslen af dit barn, 
selvom du ikke har en blødersygdom. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take novoseven"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take novoseven"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke NovoSeven </p>
<ul>
<li>
<p>Hvis du er allergisk over for eptacog alfa (det aktive stof i NovoSeven) eller et af de øvrige 
indholdsstoffer i dette lægemiddel (angivet i punkt 6). </p>
</li>
<li>
<p>Hvis du er allergisk over for muse-, hamster- eller okseproteiner (såsom komælk).  </p>
</li>
</ul>
<p>► 
Hvis nogle af disse tilstande gør sig gældende, må du ikke bruge NovoSeven. Spørg lægen til 
råds. </p>
<p>Advarsler og forsigtighedsregler 
Inden behandling med NovoSeven, skal du sikre dig, at din læge har kendskab til: </p>
<ul>
<li>
<p>Hvis du netop har gennemgået en operation </p>
</li>
<li>
<p>Hvis du for nylig har haft en knusningsskade </p>
</li>
<li>
<p>Hvis dine pulsårer er forsnævrede på grund af sygdom (åreforkalkning) </p>
</li>
<li>
<p>Hvis du har en forhøjet risiko for blodpropper (trombose) </p>
</li>
<li>
<p>Hvis du har en alvorlig leversygdom </p>
</li>
<li>
<p>Hvis du har en alvorlig blodforgiftning </p>
</li>
<li>
<p>Hvis du har vist tendens til dissemineret intravaskulær koagulation (DIC, en tilstand, hvor der 
udvikles blodpropper overalt i blodbanen), skal du være under omhyggelig overvågning. </p>
</li>
</ul>
<p>► 
Hvis nogle af disse tilfælde gør sig gældende, kontakt din læge, før du tager en injektion. </p>
<p>Brug af anden medicin sammen med NovoSeven 
Fortæl det altid til lægen eller på apoteket, hvis du bruger anden medicin eller har brugt det for nylig.  </p>
<p>Brug ikke NovoSeven samtidigt med protrombin-kompleks-koncentrater eller rFXIII. Fortæl det altid 
til lægen, inden du bruger NovoSeven, hvis du også bruger factor VIII eller IX produkter. </p>
<p>Der er kun begrænset erfaring med samtidig brug af NovoSeven og antifibrinolytisk medicin (såsom 
aminocapronsyre eller tranexamsyre), som også bruges til at kontrollere blødninger. Kontakt din læge 
inden du bruger NovoSeven med denne type medicin. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du anvender NovoSeven. </p>
<p>Trafik- og arbejdssikkerhed 
Der er ingen studier, som viser at NovoSeven har en påvirkning på evnen til at køre bil eller arbejde 
med maskiner. Der er ingen medicinsk årsag til at mistænke at det vil påvirke din evne. </p>
<p>NovoSeven indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. injektion, dvs. lægemidlet er 
stort set natriumfrit.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take novoseven"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take novoseven"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>NovoSeven pulveret skal opblandes med solvensen og injiceres i en vene. Se næste side for en 
detaljeret instruktion. </p>
<p>Ved egenbehandling 
Påbegynd behandling af en blødning så hurtigt som muligt, ideelt indenfor 2 timer. </p>
<ul>
<li>
<p>I tilfælde af svag eller moderat blødning, skal du behandle dig selv så hurtigt som muligt, ideelt 
i hjemmet. </p>
</li>
<li>
<p>I tilfælde af alvorlig blødning skal du kontakte din læge. Normalt behandles alvorlige 
blødninger på hospitalet, og du kan injicere den første NovoSeven dosis på vejen dertil. </p>
</li>
</ul>
<p>Din behandling hjemme må ikke overskride 24 timer uden konsultation hos en læge. </p>
<ul>
<li>
<p>Hver gang du bruger NovoSeven skal du hurtigst muligt indberette dette til din læge eller 
hospitalet. </p>
</li>
<li>
<p>Hvis blødningen ikke er under kontrol indenfor 24 timer, skal du straks kontakte din læge. 
Hospitalsbehandling vil normalt være nødvendig. </p>
</li>
</ul>
<p>Dosis 
Den første dosis skal gives så hurtigt som muligt efter blødningsepisodens opståen. Tal med din læge 
om, hvornår du skal tage injektionerne, og hvor lang tid behandlingen skal vare. 
Dosis fastsættes af lægen på baggrund af din legemsvægt, tilstand og blødningstype. 
For at opnå den bedste behandling, skal du følge den ordinerede dosis nøje. Din læge kan ændre dosis. </p>
<p>Hvis du har hæmofili: 
Den normale dosis er 90 mikrogram per kilo legemsvægt. Du kan gentage injektionen hver 
2. til 3. time, indtil blødningen er kontrolleret. 
Din læge kan anbefale en enkelt injektion på 270 mikrogram per kilo legemsvægt. Der er ingen klinisk 
erfaring med patienter over 65 år, der anvender denne dosis. </p>
<p>Hvis du har faktor VII-mangel: 
Den normale dosis er 15 til 30 mikrogram per. kilo legemsvægt i hver injektion.  </p>
<p>Hvis du har Glanzmanns trombasteni: 
Den normale dosis er 90 mikrogram (80 til 120 mikrogram) per kilo legemsvægt for hver injektion. </p>
<p>Hvis du har brugt for meget NovoSeven 
Kontakt omgående lægen, hvis du kommer til at injicere for meget NovoSeven. </p>
<p>Hvis du har glemt at bruge NovoSeven 
Spørg din læge til råds, hvis du glemmer en injektion, eller hvis du ønsker at stoppe behandlingen. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.  </p>
<p>Alvorlige bivirkninger<br />
Sjældne (kan forekomme ved 1 ud af 1.000 behandlinger) </p>
<ul>
<li>
<p>Allergi, overfølsomhed eller anafylaktiske reaktioner. Symptomer kan inkludere udslæt på 
huden, kløe, rødme og nældefeber, hiven efter vejret eller vejrtrækningsproblemer, føle sig svag 
eller svimmel, og alvorlig hævelse af læber eller hals, eller ved injektionsstedet. </p>
</li>
<li>
<p>Blodpropper i hjertets årer (som kan føre til hjertetilfælde eller hjertekrampe), i hjernen (som 
kan føre til slagtilfælde) eller i tarmen og nyrerne. Symptomer kan inkludere alvorlig 
brystsmerte, kortåndethed, forvirring, tale- og bevægelsesproblemer (lammelse) eller 
mavesmerte. </p>
</li>
</ul>
<p>Ikke almindelige (kan forekomme ved 1 ud af 100 behandlinger) </p>
<ul>
<li>
<p>Blodpropper i venerne i lungerne, benene, leveren, nyrerne eller ved injektionsstedet. 
Symptomer kan inkludere vejrtrækningsproblemer, rød og smertefuld hævelse af benet og 
mavesmerte. </p>
</li>
<li>
<p>Manglende virkning eller nedsat respons på behandling. </p>
</li>
</ul>
<p>► 
Hvis du opdager nogle af disse alvorlige bivirkninger, skal du søge lægehjælp øjeblikkeligt. 
Fortæl at du har brugt NovoSeven. </p>
<p>Fortæl altid lægen, hvis du tidligere har haft allergiske reaktioner, da du måske skal følges mere 
omhyggeligt. I de fleste tilfælde af blodpropper havde patienterne i forvejen tendens til 
blodpropslidelser. </p>
<p>Andre sjældne bivirkninger 
(kan forekomme ved 1 ud af 1.000 behandlinger) </p>
<ul>
<li>
<p>Kvalme (opkast) </p>
</li>
<li>
<p>Hovedpine </p>
</li>
<li>
<p>Forandringer i nogle lever- og blodanalyser. </p>
</li>
</ul>
<p>Andre ikke almindelige bivirkninger 
(kan forekomme ved 1 ud af 100 behandlinger) </p>
<ul>
<li>
<p>Allergiske hudreaktioner inklusiv udslæt, kløe og nældefeber </p>
</li>
<li>
<p>Feber. </p>
</li>
</ul>
<p>Indberetning af bivirkninger<br />
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apotekspersonalet. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store novoseven"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store novoseven"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <ul>
<li>
<p>Opbevares utilgængeligt for børn. </p>
</li>
<li>
<p>Brug ikke dette lægemiddel efter den udløbsdato, der står på pakningen. Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
</li>
<li>
<p>Pulver og solvens opbevares under 25°C. </p>
</li>
<li>
<p>Pulver og solvens opbevares beskyttet mod lys. </p>
</li>
<li>
<p>Må ikke fryses. </p>
</li>
<li>
<p>Brug NovoSeven straks efter pulveret er opblandet med solvensen for at undgå infektion. Hvis 
du ikke bruger det straks efter opblanding, skal du opbevare det i hætteglasset med 
hætteglasadapteren og injektionssprøjten påsat i køleskabet ved 2°C til 8°C i højst 24 timer. 
NovoSeven oplandingen må ikke fryses og skal opbevares beskyttet mod lys. Du må kun 
opbevare opløsningen, hvis du har rådført dig med en læge eller sygeplejerske. </p>
</li>
<li>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>
</li>
</ul>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>NovoSeven indeholder </p>
<ul>
<li>
<p>Aktivt stof: rekombinant koagulationsfaktor VIIa (aktiveret eptacog alfa). </p>
</li>
<li>
<p>Øvrige indholdsstoffer i pulveret: natriumchlorid, kalciumchloriddihydrat, glycylglycin, 
polysorbat 80, mannitol, saccharose, methionin, saltsyre, natriumhydroxid. </p>
</li>
</ul>
<p>Indholdsstoffer i solvensen: histidin, saltsyre, natriumhydroxid, vand til injektionsvæsker. </p>
<p>Pulveret til injektionsvæske, opløsning, indeholder: 1mg/hætteglas (svarende til 50 KIE/hætteglas), 2 
mg/hætteglas (svarende til 100 KIE/hætteglas), 5 mg/hætteglas (svarende til 250 KIE/hætteglas) eller 
8 mg/hætteglas (svarende til 400 KIE/hætteglas). 
Efter opblanding indeholder 1 ml opløsning 1mg eptacog alfa (aktiveret). 
1 KIE svarer til 1.000 IE (internationale enheder). </p>
<p>Udseende og pakningsstørrelser 
Hætteglasset med pulver indeholder hvidt pulver, og den fyldte sprøjte med solvens indeholder en 
klar, farveløs opløsning. Den opblandede opløsning til injektion er farveløs. Brug ikke den opblandede 
opløsning, hvis du opdager, at den indeholder partikler eller hvis den er misfarvet. </p>
<p>Hver NovoSeven pakning indeholder: </p>
<ul>
<li>
<p>1 hætteglas med hvidt pulver til injektionsvæske, opløsning </p>
</li>
<li>
<p>1 hætteglasadaptor </p>
</li>
<li>
<p>1 fyldt sprøjte med solvens til opblanding (rekonstitution) </p>
</li>
<li>
<p>1 stempelstang </p>
</li>
</ul>
<p>Pakningsstørrelser: 1mg (50 KIE), 2 mg (100 KIE), 5 mg (250 KIE) og 8 mg (400 KIE). </p>
<p>Den aktuelle pakningsstørrelse er angivet på den ydre emballage. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller 
Novo Nordisk A/S 
Novo Allé 
DK-2880 Bagsværd, Danmark </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/. </p>
<p>NovoSeven Brugervejledning  </p>
<p>LÆS DENNE BRUGERVEJLEDNING OMHYGGELIGT, INDEN DU BRUGER NOVOSEVEN </p>
<p>NovoSeven leveres som pulver. Før injektion (administration) skal det blandes (rekonstitueres) med solvens, 
der leveres i en sprøjte. Solvensen er en histidin opløsning. Det opblandede NovoSeven skal injiceres i en vene 
(intravenøs injektion). Udstyret i denne pakning er designet til at opblande og injicere NovoSeven. </p>
<p>Du behøver desuden et administrationssæt (slange og sommerfuglenål, sterile alkoholservietter, 
gazekompresser og plaster). Dette udstyr er ikke inkluderet i pakningen med NovoSeven. </p>
<p>Brug ikke udstyret uden ordentlig undervisning fra din læge eller sygeplejerske.  </p>
<p>Vask altid dine hænder og sørg for, at området omkring dig er rent.  </p>
<p>Når du klargør og injicerer et lægemiddel direkte ind i venen, er det vigtigt at anvende en ren og bakteriefri 
(aseptisk) fremgangsmetode. Forkert fremgangsmåde kan forårsage en bakterieinfektion i blodet. </p>
<p>Åbn ikke udstyret, før du er klar til at bruge det.  </p>
<p>Brug ikke udstyret hvis det har været tabt, eller er blevet beskadiget. Tag i stedet en ny pakning i brug. </p>
<p>Brug ikke udstyret hvis udløbsdatoen er overskredet. Tag i stedet en ny pakning i brug. Udløbsdatoen står 
på etiketten efter ’EXP’ på den ydre karton, på hætteglasset, på hætteglasadapteren og på den fyldte sprøjte. </p>
<p>Brug ikke udstyret hvis du har mistanke om, at det er forurenet. Tag i stedet en ny pakning i brug. </p>
<p>Smid ikke nogle af delene ud før du har afsluttet injektionen af den opblandede opløsning. </p>
<p>Udstyret er kun til engangsbrug.  </p>
<p>Indhold </p>
<p>Pakningen indeholder: </p>
<ul>
<li>
<p>1 hætteglas med NovoSeven pulver </p>
</li>
<li>
<p>1 hætteglasadaptor  </p>
</li>
<li>
<p>1 fyldt sprøjte med solvens </p>
</li>
<li>
<p>1 stempelstang (placeret under sprøjten)  </p>
</li>
</ul>
<p>Oversigt 
Plastikhætte 
Gummiprop 
(under plastikhætte) 
Hætteglas med NovoSeven 
pulver </p>
<p>Hætteglasadapter 
Beskyttelseshætte 
Spids 
(under 
beskyttelsespapir) 
Beskyttelses- papir </p>
<p>Fyldt sprøjte med solvens 
Sprøjtespids 
(under 
sprøjtehætte) 
Skala 
Stempel 
Sprøjtehætte </p>
<p>Stempelstang 
Gevind 
Bred 
ende </p>
<ol>
<li>
<p>Klargøring af hætteglasset og sprøjten </p>
</li>
<li>
<p>Tag det antal NovoSeven pakninger, du behøver.  </p>
</li>
<li>
<p>Kontrollér udløbsdatoen.  </p>
</li>
<li>
<p>Kontrollér navn, styrke og farve på pakningen for 
at sikre at den indeholder det rigtige produkt.  </p>
</li>
<li>
<p>Vask dine hænder og tør dem i et rent håndklæde 
eller lufttør dem. </p>
</li>
<li>
<p>Tag hætteglasset, hætteglasadapteren og den fyldte 
sprøjte ud af kartonen. Lad stempelstangen forblive 
urørt i kartonen. </p>
</li>
<li>
<p>Hætteglasset og den fyldte sprøjte skal have 
stuetemperatur (ikke over 37°C). Du kan gøre dette </p>
</li>
</ol>
<p>A </p>
<p>ved at holde dem i dine hænder, indtil de føles lige så 
varme som dine hænder.  </p>
<ul>
<li>
<p>Der må ikke benyttes andre metoder til at varme 
hætteglasset og den fyldte sprøjte. </p>
</li>
<li>
<p>Fjern plastikhætten fra hætteglasset.<br />
Brug ikke hætteglasset, hvis plastikhætten 
mangler eller sidder løst. </p>
</li>
<li>
<p>Tør gummiproppen på hætteglasset af med en steril 
alkoholserviet og lad den lufttørre i nogle sekunder 
før brug, for at sikre at den er så bakteriefri som 
muligt. </p>
</li>
<li>
<p>Rør ikke ved gummiproppen med dine fingre, da 
dette kan overføre bakterier.  </p>
</li>
</ul>
<p>B </p>
<ol>
<li>
<p>Påsæt hætteglasadaptoren </p>
</li>
<li>
<p>Fjern beskyttelsespapiret fra hætteglasadaptoren. </p>
</li>
</ol>
<p>Brug ikke hætteglasadaptoren, hvis 
beskyttelsespapiret ikke er helt forseglet eller er 
ødelagt.  </p>
<p>Fjern ikke beskyttelseshætten på 
hætteglasadaptoren med dine fingre. Hvis du rører 
spidsen af hætteglasadaptoren, kan det overføre 
bakterier fra dine fingre. </p>
<p>C </p>
<ul>
<li>
<p>Placér hætteglasset på en flad og fast overflade. </p>
</li>
<li>
<p>Drej beskyttelseshætten på og klik 
hætteglasadaptoren fast på hætteglasset.  </p>
</li>
</ul>
<p>Fjern ikke hætteglasadaptoren fra hætteglasset, 
efter den er påsat.  </p>
<p>D </p>
<ul>
<li>Tryk let på beskyttelseshætten med tommel- og 
pegefinger som vist på figuren. 
Fjern beskyttelseshætten fra hætteglasadaptoren. </li>
</ul>
<p>Løft ikke hætteglasadaptoren op fra hætteglasset, 
når du fjerner beskyttelseshætten. </p>
<p>E </p>
<ol>
<li>
<p>Påsæt stempelstangen og sprøjten  </p>
</li>
<li>
<p>Tag fat i stempelstangen ved den brede ende, og tag 
den ud af kartonen. Rør ikke ved siderne eller 
gevindet på stempelstangen. Hvis du rører ved 
siderne eller gevindet, kan det overføre bakterier fra 
dine fingre. </p>
</li>
</ol>
<p>Sæt straks stempelstangen ind i sprøjten, ved at dreje 
den med uret ind i den fyldte sprøjte, indtil der 
mærkes modstand. </p>
<p>F </p>
<ul>
<li>Fjern hætten fra sprøjten ved at bøje den ned, indtil 
perforeringen knækker. </li>
</ul>
<p>Rør ikke ved sprøjtens spids. Hvis du rører ved 
sprøjtens spids, kan det overføre bakterier fra dine 
fingre. </p>
<p>Brug ikke sprøjten, hvis hætten er løs eller 
mangler. </p>
<p>G </p>
<ul>
<li>Skru den fyldte sprøjte fast på hætteglasadaptoren, 
indtil der mærkes modstand. </li>
</ul>
<p>H </p>
<ol>
<li>
<p>Opblanding af pulver med solvens </p>
</li>
<li>
<p>Hold den fyldte sprøjte en smule skråt med 
hætteglasset nedad. </p>
</li>
<li>
<p>Pres stempelstangen ned for at injicere al solvensen 
ind i hætteglasset. </p>
</li>
</ol>
<p>I </p>
<ul>
<li>
<p>Hold stempelstangen nede, mens hætteglasset 
hvirvles forsigtigt rundt, indtil alt pulveret er opløst.<br />
Ryst ikke hætteglasset, da dette vil medføre 
skumdannelse. </p>
</li>
<li>
<p>Tjek den opblandede injektionsvæske. Den skal 
være farveløs. Brug den ikke, hvis der er visuelle 
partikler eller misfarvning. Brug en ny pakning i 
stedet.  </p>
</li>
</ul>
<p>J </p>
<p>Brug det opblandede NovoSeven straks for at undgå infektioner.  </p>
<p>Hvis du ikke kan bruge det straks, se punkt </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-beff2655528d75e602c405816fbf6082
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for novoseven Package Leaflet for language en"
Description: "ePI document Bundle for novoseven Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-beff2655528d75e602c405816fbf6082"
* entry[0].resource = composition-en-beff2655528d75e602c405816fbf6082

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpbeff2655528d75e602c405816fbf6082"
* entry[=].resource = mpbeff2655528d75e602c405816fbf6082
                            
                    
Instance: bundlepackageleaflet-da-beff2655528d75e602c405816fbf6082
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for novoseven Package Leaflet for language da"
Description: "ePI document Bundle for novoseven Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-beff2655528d75e602c405816fbf6082"
* entry[0].resource = composition-da-beff2655528d75e602c405816fbf6082

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpbeff2655528d75e602c405816fbf6082"
* entry[=].resource = mpbeff2655528d75e602c405816fbf6082
                            
                    



Instance: mpbeff2655528d75e602c405816fbf6082
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection"
Description: "NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "NovoSeven 1 mg (50 KIU)"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: beff2655528d75e602c405816fbf6082ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "novoseven"

* status = #current
* mode = #working

* title = "List of all ePIs associated with novoseven"

* subject = Reference(mp19f202467812b15f4eac52e395f85d01)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#novoseven "novoseven"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-beff2655528d75e602c405816fbf6082) // novoseven en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-beff2655528d75e602c405816fbf6082) // novoseven da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-beff2655528d75e602c405816fbf6082
InstanceOf: List

* insert beff2655528d75e602c405816fbf6082ListRuleset
    